Literature DB >> 10320471

Mood Disorder Due to Human Immunodeficiency Virus: Yes, No, or Maybe?

.   

Abstract

The potential for secondary (biological or psychological) mood disorders would seem to be heightened in human immunodeficiency virus (HIV) for many reasons. HIV infection is associated with lethal, multisystem illness related to profound immune dysregulation; infection involves the central nervous system (CNS) shortly after infection and leads to substantial neurocognitive impairment even in the absence of other physical evidence of disease. Psychological forces at work include social stigimitization of unparalleled proportion for the modern era, combined with bereavements of epidemic proportions, Nevertheless, it is misleading to attribute to HIV itself-or to its psychological and social consequences-all episodes of mood disorder. Preinfection rates of major depression are high in groups at greatest risk for HIV. Rates of "current" major depression approach 10%, but perhaps 50% of affected individuals have preinfection evidence of mood disorder. Mania is relatively rare, with an overall prevalence less that 1%. "Subsyndromic" mood disorder is understudied, but may effect an important minority of individuals. Given current advances in neuromedical evaluation, neuropsychological assessment, and rigorous psychiatric criteria, it is likely that study of secondary mood disorders in HIV can contribute to important advances in our understanding of brain-behavioral relationships.

Entities:  

Year:  1997        PMID: 10320471     DOI: 10.1053/SCNP00200276

Source DB:  PubMed          Journal:  Semin Clin Neuropsychiatry        ISSN: 1084-3612


  2 in total

Review 1.  Affective disorders in patients with HIV infection: impact of antiretroviral therapy.

Authors:  Gabriele Arendt
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

2.  Validity of the Hopkins Symptom Checklist-25 amongst HIV-positive pregnant women in Tanzania.

Authors:  S F Kaaya; M C S Fawzi; J K Mbwambo; B Lee; G I Msamanga; W Fawzi
Journal:  Acta Psychiatr Scand       Date:  2002-07       Impact factor: 6.392

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.